Jubilant Life Sciences has dipped over 6% to Rs 174, falling 8.4% from intra-day high, after the company said that it has received a warning letter for one of its manufacturing facility located in Canada.
“Jubilant HollisterStier General Partnership (JHS) located at Kirkland, Quebec, Canada has been issued a warning letter by US Food and Drug Administration (FDA) identifying significant violations of current Good Manufacturing Practices (cGMP) Regulations,” Jubilant Life Sciences said in a filing.
The company will respond to this warning letter on or before March 15, 2013, it added.
Meanwhile, the company expects that the on-going manufacturing, distribution and sale of products will not be affected by this warning letter.
JHS is committed to implementing the necessary corrective actions required to address the FDA concerns, and will work closely with the FDA to bring resolution to this matter, the company said.
The stock opened at Rs 189 and hit a high of Rs 190 on NSE. A combined 256,042 shares have already changed hands on the counter so far against an average less than 100,000 shares that were traded daily in past two weeks.
“Jubilant HollisterStier General Partnership (JHS) located at Kirkland, Quebec, Canada has been issued a warning letter by US Food and Drug Administration (FDA) identifying significant violations of current Good Manufacturing Practices (cGMP) Regulations,” Jubilant Life Sciences said in a filing.
The company will respond to this warning letter on or before March 15, 2013, it added.
Meanwhile, the company expects that the on-going manufacturing, distribution and sale of products will not be affected by this warning letter.
JHS is committed to implementing the necessary corrective actions required to address the FDA concerns, and will work closely with the FDA to bring resolution to this matter, the company said.
The stock opened at Rs 189 and hit a high of Rs 190 on NSE. A combined 256,042 shares have already changed hands on the counter so far against an average less than 100,000 shares that were traded daily in past two weeks.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%